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SUMMARY  
Non-Homologous End-Joining (NHEJ) is the major DNA repair pathway that senses, 
processes and ligates DNA double strand breaks (DSBs) in higher eukaryotes, functionally 
throughout the cell cycle. The NHEJ involves four core and some accessory factors. The 
accessory factors are mainly required for resolving specific types of lesions. During NHEJ, 
core Ku70 and Ku80 subunits bind DSBs as a heterodimer and promote further recruitment 
of accessory factors (e.g., XLF, PAXX, MRI, DNA-PKcs, Artemis) and downstream core 
subunits XRCC4 and DNA ligase 4 (Lig4). Paralogue of XRCC4 and XLF (PAXX) has 
shown to be redundant with the XRCC4-Like Factor (XLF).  
Inactivation of Ku70 or Ku80 genes in mice results in immunodeficiency and high levels of 
genomic instability. While knockout of individual Xlf or Paxx in previously published mouse 
models revealed no overt phenotype, combined Xlf and Paxx deficiency results in late 
embryonic lethality (E15.5) due to extensive apoptosis in the central nervous system. These 
findings indicate important overlapping functions among the two proteins.  
The first aim of this project was to investigate if the lethality of Xlf-/-Paxx-/- mice can be 
rescued by inactivating one or two alleles of Trp53. This was done by crossbreeding Xlf+/-
Paxx+/-Trp53+/- mice and verified by gene and protein expression.  
The second aim of this project was to describe the impact of Xlf and Paxx in immune system 
and general mouse development. Our Xlf-/-Paxx-/- mice with deficiency for one or two alleles 
of Trp53 were here found to be distinguishable from single knockout Xlf-/- and Paxx-/- and 
heterozygous mice in relation to growth and lymphoid cell counts in the spleen and thymus. B 
and T cell frequencies in the spleen and thymus of Xlf-/-Paxx-/-Trp53+/- mice were evaluated in 
order to determine precisely the effect of Xlf and Paxx inactivation on lymphocyte 
development. I detected no B cells in the spleens and thymi of double knockout mice. 
However, I detected CD4+ and CD8+ T cells in both organs, in addition to nearly normal 
CD4+CD8+ T cell frequency. Furthermore, Xlf-/-Paxx-/-Trp53+/- TFs were evaluated every 48 
hours until the sixth day in order to identify the proliferative power of Xlf-/-Paxx-/- cells. Xlf-/-
Paxx-/-Trp53+/- TFs showed a significantly reduced proliferation compared to heterozygous 
and single knockout controls. 
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Additionally, an optimization of the T-FISH technique was established in order to identify 
genomic instability at the chromosomal level. Some technical improvements in the assay 
allowed me to identify that Xlf-/-Paxx-/-Trp53+/- mice possess high numbers of 
chromosomal/chromatid breaks compared to heterozygous and single knockout controls. 
However, the small number of used samples did not allow me to make a solid conclusion and 
more mice are required to complete the study. 
In conclusion, I demonstrated that inactivation of pro-apoptotic factor Trp53 rescues 
embryonic lethality of Xlf−/−Paxx−/− double knockout mice. 
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1. INTRODUCTION 
1.1 The Immune System 
The immune system has as a major task to protect the individuals from environmental agents, 
such as microbes or chemicals, preserving the integrity of the host [1]. However, it has other 
relevant functions as well, like the following ones [2]: 
1. Memory function, providing long-lasting security against infection. 
2. It does not attack its own tissues or put its beneficial cohabitants in jeopardy. 
Furthermore, the immune system, depending on the specificity and speed of the required 
reaction activates two classes of responses, innate and adaptive responses, even though, the 
interaction between them is high[3].  
The innate immune system provides immediate host defense and is highly conserved 
evolutionarily. It consists of physical, chemical and microbiological barriers. Moreover, the 
innate immunity includes characteristic elements, such as macrophages, neutrophils, 
monocytes, and cytokines, among others. Nevertheless, the reactions carried out by this 
immune system can cause damages and injuries to normal tissues given the lack of 
specificity[4].  
On the other hand, the second class of immunity is highlighted for being present in higher 
animals and human beings. Adaptive response can take from days to weeks; however, they 
are accurate because of the antigen specificity carried out by B and T lymphocytes. One of 
the major responses long-term is the lymphocytic memory; allowing rapid and effective 
responses to repeated exposures [5].  
Furthermore, the immune system organs are divided in two groups, primary and secondary 
immune organs. The primary organs of the immune system include the thymus and bone 
marrow, while the secondary lymphatic tissues include spleen, tonsils, lymph vessels, lymph 
nodes, adenoids, skin, and liver[6].  
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1.2 The adaptive immune system and lymphocyte 
development 
The adaptive immune system is highly regulated by the interaction between antigen-presenting 
cells and the B and T lymphocytes. This system protects the host through several 
characteristics such as immunologic memory, specific effector pathways and regulation of the 
homeostasis [7, 8].  B and T lymphocytes are derived from specific types of stem cells called 
hematopoietic stem cells (HSCs) in the bone marrow. Developing B cells pass through 
several stages in order to acquire their antigen specificity in the absence of any exogenous 
antigen [9, 10]. Differently, T cells develop in the thymus, another primary immune organ 
[11, 12] (Figure 1). 
Development and activation of B and T lymphocytes depends on a process which involves 
genetic rearrangement in the variable (V), diversity (D) and joining (J) gene segments, 
known as V(D)J recombination. V(D)J recombination leads to the enormous repertoire of  B 
and T cell receptors, that are able to recognize specific antigens[7].  
 
Figure 1: Simplified overview of B and T lymphocyte development. Hematopoeitic stem cells (HSCs) further 
develop to T cell precursors and Pro-B cells. Pro-B cells maturate to B cells after successful V(D)J 
recombination, dependent on the NHEJ. T-pre cells migrate to thymus and maturate to T cells. * Cell subset 
explanation is provided in the sections 1.2.2 and 1.2.3. Image inspired from the book by Kindt Thomas, 
Goldsby Richard and Osborne Barbara. Kuby Immunology, sixth edition, New York, USA. W.H Freeman and 
Company[6]. 
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1.2.1  V(D)J Recombination 
V(D)J recombination is a physiological mechanism which is fundamental for the development 
and maturation of B and T cells. V(D)J recombination requires DNA double strand breaks 
(DSBs) to trigger the recombination. This process involves the generation of different 
combinations of the V(D)J pre-existing gene segments. This pathway includes cleavage within 
specific recombination signal sequence (RSS) by the recombination activating gene 1 and 2 
proteins (RAG1 and RAG2), operating as a complex called RAG. The V(D)J recombination 
preferentially occurs in the first gap phase (G1) of the cell cycle, because RAG2 protein is 20-
fold more abundant in G1 phase than in the mitosis (M), second gap phase (G2) or synthesis 
phase (S) of the cell cycle in both precursors of B or T lymphocytes[13]. 
The RSSs are composed of three elements; a heptamer of seven conserved nucleotides, a 
spacer region of 12 or 23 base pairs, and a nonamer of nine conserved nucleotides. Initially, 
RSSs flank the V, D and J gene segments then; the segments are rearranged next to each 
other during the resolution of these DSBs. Consequently, they are rejoined, almost 
exclusively by the classical-NHEJ factors (explained in the section 1.3.2) resulting in a V(D)J 
gene segment[14, 15](Figure 2). 
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Figure 2: Simplified overview of V(D)J recombination. Gene segments are flanked by a 12 or 23 RSS 
recombination signal sequence (12 or 23 RSS). RAG1 and RAG2 proteins bind to the 12 RSS and the 23 RSS, 
forming the 12 signal complex or the 23 signal complex, respectively. Capture of the second RSS (a process 
termed synapsis) results in the formation of the paired complex, within which the RAG proteins introduce 
double strand breaks between the gene segments and the RSSs. Then, the non-homologous end joining 
(NHEJ) DNA repair factors rejoin the DNA ends into a coding joint. RSS ends are joined without processing 
to form the signal joint. Figure based on Schatz, D. G., & Ji, Y. (2011). Recombination centres and the 
orchestration of V (D) J recombination. Nature reviews immunology, 11(4), 251.[16].  
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1.2.2 B cells 
The B-cell development, both in humans and mice involves genetic rearrangements by 
acquiring antigenic specificity. Initially, the development of B cells begins in the fetal liver and 
continues in the bone marrow throughout our lives[17]. B cell development results in the 
production of a diverse collection of functional B-cell receptors (BCR)[18, 19]. 
The BCR is composed of two heavy (H) chains and two light (L) chains, κ or λ. The 
development of  the BCR includes rearrangement of the V, D, and J gene segments in the H 
chain locus and the V and J gene segments in the L chain loci[10] (Figure 3). BCRs play role 
in the B-cell development, survival, and activation of B cells. 
The BCR formation occurs in three developmental stages, pro-B, pre-B and immature B 
stage. Progenitor B (pro-B) cells develop to Pre-B cells, and the latter express pre-BCR. 
When the BCR process finishes (expressing cytoplasmic μH chains, also called 
immunoglobulin M (IgM)), B cells are immature and ready to interact with antigens (Ag) and 
become mature-B cells (Figure 4). The B-cell activation induced by Ag is carried out in 
secondary lymphoid tissues, for example in the spleen. A process called class switch 
recombination (CSR), or isotype-switching, leads to changes in the H chains, for instance, 
from IgM to IgA, IgE or IgG, giving rise to different effector functions depending on the 
recognized Ag [20]. 
Through the development of B cells, the different stages express co-receptors, such as CD43 
and B220. However, CD19, a transmembrane glycoprotein, is the co-receptor expressed in 





Figure 3: V(D)J recombination in B cells. The B cell receptor (BCR) is composed of two heavy chains (blue) 
and two light chains (red). In heavy chains the D-J recombination takes place in early pro-B cells followed by 
V-DJ recombination in late pro-B cells. In light chains V-J recombination occurs in small pre-B cells. V: 
Variable gene segments, D: diversity segments, J: joining segments and C: Constant Igh gene region. Figure 
modified from the book by Peter Parham. The Immune System, third edition. Garland Science[22]. 
 
 
                 
Figure 4: B-cell development from early pro-B cells to immature B cells. Formation of BCR signaling by 
V(D)J recombination. Rearrangements of the D and J gene segments in the immunoglobulin heavy chains 
occurs in early pro-B cells, followed by V segment rearrangement in the late pro-B cells forming the Pre-BCR 
on large pre-B cells. The last rearrangement takes place in small pre-B cells in the V and J segments 
producing the BCR signaling on immature B cells. CD19 is a co-receptor expressed on late pro-B cells, large 
pre-B cells, small pre-B cells and immature B cells. Figure inspired from Holmes, M. L., Pridans, C., & Nutt, 
S. L. (2008). The regulation of the B-cell gene expression programme by Pax5. Immunology and cell 





1.2.3 T cells 
Hematopoietic stem cells in the bone marrow originate T-cell precursors (T-pre cells), which 
develop to T cells. T-pre cells migrate and colonize the thymus. In the thymus, the precursors 
of T cells undergo a developmental process with the purpose to maturate and express the T 
cell receptor (TCR). Approximately 95 % of the T cells in the thymus give rise to αβ T cells, 
however approximately 5% will express the γδ T cell receptor (TCR) (Figure 5). V, D and J 
variable gene segments are assembled into the β and δ receptor chains, whereas the α and γ 
receptor chains are constituted of V and J variable regions[6]. 
 
Figure 5: The T cell receptor (TCR) is composed of a combination of α and β chains or γ and δ chains in the 
variable region of the receptor. Constant regions are identical in both kinds of receptors. Figure modified from 
Matos, T. R., de Rie, M. A., & Teunissen, M. B. (2017). Research techniques made simple: high-throughput 
sequencing of the T-cell receptor. Journal of Investigative Dermatology, 137(6), e131-e138[24]. 
 
T-cell precursors give rise to double negative (DN) cells; DN cells lack expression of the co-
receptors CD4 and CD8. The DN T cells can be sub-divided into four subsets (DN1-4). DN 
T population is characterized according to the expression of receptors such as c-kit (a 
receptor tyrosine kinase), CD44 (an adhesion molecule) and CD25 (Interleukin-2 receptor α 
chain). The Figure 6 shows the ordered expression of these markers in the four types of DN T 
cells[6]. 
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V(D)J rearrangement is initiated in DN2 T cells, specifically in the β chain locus culminating 
in DN3 T cells. The latest cells undergo a process called beta-selection. This process of 
selection allows an accurate and successful rearrangement in the TCR-β chain locus.  The 
β chain pairs with the surrogate chain, pre-Tα, producing a pre-TCR, which forms a complex 
with the protein complex CD3. Cells that do not endure beta-selection die via 
apoptosis. When β-chain rearrangement is completed, DN3 T cells turn into DN4, leading to 
the survival, proliferation, and further differentiation in double positive (DP) cells by up-
regulation and expression of CD4 and CD8. Immediately, DP cells stop proliferating, and 
start the rearrangement of the V and J segments in the α chain locus, increasing the protein 
levels of RAG-2, which is essential for the maturation of T lymphocytes. Moreover, RAG-2 is 
regulated by phosphorylation to induce its degradation upon entry S phase [25]. DP T cells 
maturate into single positives (SP) CD4+ (T helper – TH) or CD8
+ (T cytotoxic or TC) T cells 
depending on the different cell interactions. The TH and TC activate B cells and lyse infected 
target cells, respectively[6, 26] . 
 
Figure 6: Development of T cells from double negative (DN) cells to CD4+ or CD8+ T cells in the thymus, 
showing αβ T cell development and the different cell surface markers expressed at the different stages of T 
cell maturation in mice. Figure modified from Divya K. Shah, Sunnybrook Research Institute, Toronto 
Canada. T-cell development in thymus. British Society for Immunology [26]. 
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1.2.4 Lymphoid Cell Frequencies 
The process of B and T cell maturation takes places in the primary immune organs, bone 
marrow and thymus, respectively. However, the activation of B-lymphocytes occurs in the 
spleen, a secondary lymphoid organ. 
By flow cytometry, it has been possible to identify the distinct cell types which reside both in 
the spleen and thymus. In the spleen, there are mainly red blood cells (RBC), B cells, CD4+ T 
cells (TH) and CD8
+ T cells (TC). Moreover, in the thymus there are both immature 
CD4+CD8+ T cells and mature T cells (CD4+ or CD8+) [27]. The Table 1 shows the 
expected frequencies of B and T lymphocytes both in the spleen and thymus in mice. 
 
Table 1: Expected B and T cell frequencies (%) in the spleen and thymus of adult mouse. Table based on Bio-
rad. Flow Cytometry – Cell frequency.2017[27] 
Spleen Thymus 
Cell type Percent % Cell type Percent % 
T cells 21 - 35 CD4+ 4 - 6  
CD4+ 13 - 20 CD8+ 1 - 2 
CD8+ 7 - 15 CD4+ CD8+ 85 - 95 






1.3 DNA Repair 
DNA repair maintains the genomic stability, preventing an uncontrolled cellular death, 
premature cell aging, degenerative changes, chromosomal aberrations and immunodeficiency.  
However, endogenous and exogenous agents constantly damage the primary structure of the 
DNA, giving rise to simple and complex changes in the DNA, from base changes to 
chromosomal aberrations, thus an accurate DNA repair is necessary  for homeostasis [28].  
Depending of the agent nature, the DNA damages can cause single-strand breaks (SSBs) or 
double-strand breaks (DSBs). Nevertheless, several strategies are utilized for its recognition 
by activating particular DNA repair pathways with the aim to trigger proper responses [29, 
30]. 
1.3.1 DNA Double-Strand Breaks (DSBs) 
DSBs are one of the most lethal type and deleterious forms of DNA damage. They can be 
originated in response by both exogenous and endogenous agents[31]. DBSs are produced 
physiologically through normal processes both in developing lymphocytes (B and T cells) by 
V(D)J recombination and in mature B cells by immunoglobulin class-switching. Furthermore, 
the repair of DSBs in eukaryotic cells is carried out by two main pathways, non-homologous 
end joining (NHEJ) and homologous recombination (HR)[32, 33].  
NHEJ is the major mammalian DSB repair pathway, which is active throughout the whole cell 
cycle, especially in the G1 of the cell cycle. Meanwhile, HR is the main DSB repair pathway 
used during the S and the G2 phases when sister chromatids are available and intact. 
Therefore, the cell chooses which pathway is better to repair DSBs depending on the phase of 
the cell cycle where cell is present [31, 34] . 
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1.3.2 Non-Homologous End-Joining (NHEJ) 
NHEJ consists of both the classical-NHEJ (C-NHEJ) and the alternative-NHEJ (A-NHEJ) 
pathways. NHEJ is the major system to repair DSBs in higher eukaryotes and is active during 
all phases of the cell cycle, being most important during the G1 phase [34]. This pathway is 
formed by the core and accessory factors to repair DSBs. The core factors are also called 
essential factors, and are made up of four proteins, Ku70, Ku80, X-ray repair cross-
complementing protein 4 (XRCC4), and DNA ligase IV (LIG4); the first two proteins form 
the heterodimer Ku70/Ku80 (Ku). The accessory NHEJ factors include DNA-dependent 
protein kinase catalytic subunit (DNA-PKcs), Artemis (an essential nuclease during V(D)J 
recombination in lymphocytes), XRCC4-like factor (XLF/Cernunnos, sometimes also 
regarded as core factor), Paralogue of XRCC4 and XLF (PAXX/XLS), and Modulator of 
retroviral infection (MRI/Cyren)[30, 35] (Figure 7). C-NHEJ pathway can be divided to three 
distinct stages. First, the recognition of the DSBs; second, the processing to remove 
overhangs and hairpins; and third, a DNA ligation.  
Initially, the Ku heterodimer binds the DSBs acting as a DNA damage sensor and stabilizing 
the DNA ends [36]. In addition, Ku inhibits alternative DNA repair pathways such as HR and 
A-NHEJ [37]. Furthermore, Ku recruits and activates DNA-PKcs forming a holoenzyme 
(DNA-PK). DNA-PKcs auto-phosphorylates itself and phosphorylates other C-NHEJ factors 
[38, 39]. PAXX binds and stabilizes the Ku complex [40]. Finally, XLF interacts both with 
Ku and the XRCC4–LIG4 complex stimulating DNA ligation [41, 42]. In patients, it has been 
reported that a partial loss of NHEJ genes is characterized by microcephaly, 
immunodeficiency and, cancer susceptibility [43-46]. 
A-NHEJ also repairs double-strand breaks, however, it is characterized by microhomology-
mediated  ligation with length of homology regions ranging from 1 to 25 base pairs (bp). 
Unlike C-NHEJ, A-NHEJ relies on other factors and its composition is not fully understood 
yet [47]. Usually, A-NHEJ is associated with chromosome abnormalities such as deletions, 
translocations and inversions [48]. However, the high abundance of Ku in cells increases 
the likelihood that Ku is the first protein to bind to a broken DNA ends and, by 




Figure 7: Simplified overview of the NHEJ pathway. A)  DNA double strand breaks caused by genotoxic 
factors. Chemically modified DNA ends (red circles) are ready to be processed. B) Ku heterodimer 
(Ku70/Ku80) recognizes and binds tightly to both DNA ends. C) Ku recruits DNA-PKcs forming a synapse 
between the DNA ends. D) Stabilization of the complex by binding of accessory factors XLF and PAXX. E) 
End-processing and ligation by XLF and two core factors, XRCC4 and LIG4. F) Removal of the protein 
complex. Ku70: blue, Ku80: light blue, DNA-PKcs: brown, XLF: yellow, PAXX: green, XRCC4: purple and 
Lig4: gray color. This figure is based on Rulten, S. L., & Grundy, G. J. (2017). Non-homologous end joining: 





1.3.3 NHEJ factors: XLF and PAXX 
In 2006, a scientific group reported five patients with mutations in a new protein, initially 
called Cernnunos or XLF, which resulted in a new syndrome associated with 
immunodeficiency, B and T lymphocytopenia, growth retardation, and microcephaly [43]. In 
addition, in the same year, another group discovered XLF as a NHEJ factor. 
XLF interacts with the core factors XRCC4 and Lig4 during the DNA ligation [51]. 
Nevertheless, in a mouse model, the lack of XLF does not result in the same phenotype as in 
humans. In particular, the V(D)J recombination in B and T cells is carried out with wild type 
rates in the absence of XLF, moreover, mature lymphocyte number in XLF-deficient mice is 
only modestly decreased [52, 53]. 
In 2014-2015, three independent groups reported a new protein initially called C9orf142, 
XLS (XLF-like small protein), or PAXX (Paralogue of XRCC4 and XLF). The structural 
similarities between PAXX and XLF are shown in the Figure 8. However, regardless of the 
structural similarity, PAXX shares little sequence homology with XLF and XRCC4 [40, 54, 
55]. During NHEJ, PAXX is rapidly recruited to the DNA damage sites, promotes the Ku 
binding at DNA ends by stabilizing the NHEJ machinery, and cooperates with XLF [40]. 
Despite that, PAXX does not interact directly with XLF or with the core factors XRCC4 and 
Lig4 [55, 56]. Paxx knockout mice showed to be fertile with a normal growth and a mild 
sensitivity to radiation [56-59]. 
Finally, XLF-deficient human patients possess extreme sensitivity to IR, microcephaly, and 
growth retardation, nevertheless, the effects are variable on the immune system [43, 60]. This 
year 2019, Recio, M., et al., reported two unrelated cases diagnosed with the same non-sense 
mutation, but with significant differences in the immunological profile. The first patient 
showed a senescent phenotype and impaired T-cell development, whereas the second patient 
only had a slight reduction in T-cell counting [61]. Until now, there is no reported cases of 
PAXX-deficiency in humans, however, the patients with mutated PAXX might be identified 




Figure 8: Simplified overview of the predicted crystal structures of XLF and PAXX. A)  3D structural model 
of PAXX (Paralogue of XRCC4 and XLF). B) 3D structural model for XLF. This figure is based on Craxton, 
A., et al. "XLS (c9orf142) is a new component of mammalian DNA double-stranded break repair." Cell death 
and differentiation 22.6 (2015): 890 [54]. 
 
Mature B cell lacking XLF possess 2-3 fold reduction of CSR levels, while lack of PAXX had 
no effect on the CSR to IgA and IgG1 [53, 58, 62, 63].  Nevertheless, XLF and PAXX are 
functionally redundant during the V(D)J recombination in B and T lymphocytes[62, 64]. In 
vitro works reported that Xlf-/- Paxx-/- cells had more radiosensitivity compared to Xlf-/- and 
Paxx-/- cells. However, a double knockout of Xlf and Paxx in a mouse model was 
embryonically lethal due to increased apoptosis in central nervous system [56, 57, 59, 65]. 
This suggests that XLF and PAXX have overlapping functions. 
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1.3.4 Relation between p53 signaling and NHEJ factors 
Tumor protein p53, also called transformation related protein 53 (Trp53) in mice has been 
described as "the guardian of the genome" because of its role in conserving genomic stability. 
Moreover, Trp53 senses and reacts to DNA damages through the ATM/ATR and Chk1/Chk2 
kinases[66]. For example, ATM is activated in the presence of the DNA damage response 
(DDR), phosphorylates p53 and promotes the cell cycle arrest, apoptosis, and controls the 
proliferation of DNA damaged cells. If the DNA is repaired, the cells will go to S phase of the 
cell cycle. If the cells endure with DNA damage, they will undergo apoptosis mediated 
through the p53 pathway[67].  
Deficiency for Ku70, Ku80, XLF, PAXX, DNA-PKcs, Artemis and MRI results in viable 
mice, while inactivation of XRCC4 or Lig4, as well as combined inactivation of XLF/PAXX, 
XLF/DNA-PKcs and XLF/MRI leads to late embryonic lethality likely due to severe 
apoptosis in the central nervous system [35, 53, 57, 68-74](Table 2).  
However, inactivation of one or two alleles of p53 partially rescued this embryonic lethality 
[65, 71, 75, 76], highlighting the interaction between p53 and NHEJ during growth and 
development. 
Table 2: Summary of in vivo NHEJ knockout models in mice, indicating viability. Additionally, it is 
mentioned if the absence of Trp53 can partially rescue the lethality or not. 
Knockout model Viable Viable when lacking Trp53  
Ku70-/- Yes  
Ku80-/- Yes  
Xrcc4-/- No Yes 
Lig4-/- No Yes 
Xlf-/- Yes  
Paxx-/- Yes  
Dna-pkcs-/- Yes  
Mri-/- Yes  
Artemis-/- Yes  
Xlf-/- Mri-/- No Unknown 
Xlf-/- Dna-pkcs-/- No Yes 




Knocking out of one gene, Xlf or Paxx results in viable mice with modest or no phenotype, 
nevertheless, a combined deficiency for XLF/PAXX results in embryonic lethality due to 
extensive apoptosis in the central nervous system [56, 57, 59]. The lethality in mouse models 
lacking XRCC4, Lig4 or XLF/DNA-PKcs has been rescued by inactivating of one or two 
alleles of Trp53 [71, 75, 76]. Therefore, the following objectives are proposed: 
1. The first aim of this project is to investigate if the late embryonic lethality of Xlf-/-
Paxx-/- mice can be partially or completely rescued by inactivating of one or two 
alleles of Trp53. This model allows studying XLF and PAXX double-deficiency in 
vivo.  
2. If the absence of Trp53 rescues the embryonic lethality of Xlf-/-Paxx-/- mice, the 
second aim would be to characterize the model and the impact of combined 
Xlf/Paxx-inactivation on growth and immune system development in vivo. The 
following specific objectives are proposed: 
1. To analyze the lymphoid cell counts, weight of spleen, thymus and 
body, of Xlf-/-Paxx-/- mice compared to WT, heterozygous and single-
deficient controls. 
2. To determine the impact of combined Xlf and Paxx-inactivation on 
lymphocyte development, B and T cell frequencies in spleen and 
thymus, compared to WT, heterozygous and single knockout controls. 
3. To characterize the proliferative power of cells in the double deficient 
Xlf-/- Paxx-/- mice and controls. 
4. To optimize the Telomere Fluorescence in situ hybridization (T-FISH) 
technique and to investigate the genomic instability in double deficient 
and control cells at the chromosomal level. 
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3. MATERIALS AND METHODS 
3.1 Mouse models 
All experiments involving mice were performed according to the protocols approved by the 
Norwegian University of Science and Technology (NTNU). Xlf+/−[53], Paxx+/−[58], 
Trp53+/−[77], Ku80+/−[69] and Dna-pkcs+/−[68] mice were previously described. Primer 
sequences for genotyping and expected amplicons are provided in Appendix A. 
3.2 Genotyping 
3.2.1 DNA extraction and  Polymerase Chain Reaction (PCR) 
Ear-samples from mice were incubated overnight at 56°C with 2% Proteinase K solution (20 
mg/mL) (Cat#AM2546, Ambion™) and 98% DNA lysis buffer (10mM Tris pH 9.0, 1M KCl, 
0.4% NP-40, 0.1% Tween20) to extract DNA. Then, samples were incubated at 95°C for 30 
minutes and centrifuged at 15 000 rpm for 15 minutes, and the DNA concentration was 
measured by a Nanodrop® ND-1000 Spectophotometer (Thermo Scientific, Waltham, 
Massachusetts, USA). Samples where diluted to get a final DNA concentration of 
approximately 50ng/μL. The PCRs were performed with 50ng DNA in a final reaction 
volume of 25μL, using the GoTaq® G2 Green Master Mix (Promega, Madison, USA). PCRs 
were run in a 2720 Thermal Cycler (Applied Biosystems™, Foster City, California, USA). 
PCR programs are provided in Appendix B. 
 
3.2.2 Electrophoresis  
Agarose gels with GelRed™ Nucleic Acid Gel Stain (diluted from 10 000x stock, Biotium, 
Fermont, California, USA) were prepared from 0.8% SeaKem® LE Agarose (Cat#50000, 
Lonza, USA) in Tris-Borate-EDTA (TBE) buffer (pH 8.4; 89mM Tris; 89mM Boric Acid; 
2mM EDTA). Gel electrophoresis were run in TBE buffer at 124V for 75 minutes (100mL 
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gels), and the sample volume loaded was 10μL (~20ng DNA). For reliability, positive (WT 
sample), negative (knockout samples) controls and water were used in all assays. Quick-
Load® 100bp DNA Ladder (Cat#N0467S, New England Biolabs® Inc.) and Orange G 5x 
~50bp (15% glycerol; 0.2% Orange G dye, dH2O) were used as the ladder and tracking dyes, 
respectively. The gels were visualized and pictured with a Gel Logic 200 Imaging System 
(KODAK, USA). 
3.3 Extraction and concentration of proteins 
3.3.1 Protein extraction from cell culture 
Samples from primary tail fibroblast cell culture were centrifuged at 1200 rpm for 5 minutes 
at 4°C. Pellets were gently re-suspended in 1mL of Phosphate-Buffered Saline (PBS) 
(Cat#10209252, Thermo Fisher Scientific) and centrifuged at 5000 rpm x 3 minutes x 4°C. 
Pellets were re-suspended in 96% of RIPA lysis buffer (Cat#R0278, Sigma Life Science) and 
4% Complete EDTA-free Protease Inhibitor Cocktail diluted from 25x stock (Cat#P8340, 
Sigma-Aldrich) and incubated on ice for 30 minutes. Samples were centrifuged at 13000 rpms 
for 15 minutes at 4°C. Supernatants were collected and stored at -80°C. 
 
3.3.2 Bradford curve and measurement of protein concentration  
Protein concentration was determined by a Bradford assay, using Protein Assay Dye Reagent 
(Cat#5000002, Bio-Rad). The absorbance was measured at 595nm in a UV-1700 
Spectrophotometer (Shimadzu, Kyoto, Japan). The final protein concentration was calculated 
and based on the standard curve of bovine serum albumin (BSA). Preparation of BSA 
standards and measured absorbance is presented in the Table 3 and 4, respectively. The BSA 







Table 3: Preparation of BSA standards. The Protein Assay Dye Reagent was diluted five times in dH2O prior 
to measurements. A stock solution of BSA (2μg/μL) was used. 
 Standards 
1 2 3 4 5 6 
BSA (µg)/sample 0 2 4 10 14 22 
Stock BSA (μL) 0 1 2 5 7 11 
H2O (μL) 20 19 18 15 13 9 
5x diluted Protein Assay  





Table 4: Measured absorbance of BSA standards. The absorbance was measured at 595nm for BSA standards 
of 0, 2, 4, 10, 14 and 22μg.  
 Standards 
BSA (μg) 0 2 4 10 14 22 





Figure 9: BSA standard curve. The equation, y = 0,0468x + 0,0328; R2 = 0.9953, was used to estimate the 
protein concentration in cell lysates from tail fibroblasts. 
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In order to determine the concentration of my samples; the same protocol was followed but 
with 19μL dH2O, 1μL of sample, and 1000μL Protein Assay Dye Reagent (diluted 5x in 
dH2O) mixed prior to absorbance measurements. The final protein concentration was 
calculated from the BSA standard curve. 
3.4 Western blot  
3.4.1 Electrophoresis  
Western blots were prepared using around 50μg of protein samples and mixing them with 
NuPAGE® LDS Sample Buffer (originally 4x stock, Cat#NP0007, Invitrogen™) and 0.1M 
DTT (Cat#707265ML, Thermo Scientific), followed by an incubation of 10 minutes at 70°C. 
The samples were run in 4-12% Bis-Tris NuPAGE™ gels (Cat#NP0323, Thermo Fisher 
Scientific, Waltham, Massachusetts, USA) at 200V for 55 minutes in NuPAGE™ MOPS 
SDS Running Buffer (diluted from 20x stock, Cat#NP001, Thermo Fisher Scientific). 
MagicMark™ XP Western Protein Standard (Cat#LC5603, Invitrogen™) and SeeBlue™ 
Plus2 Pre-stained Protein Standard (Cat#LC5625, Invitrogen™) were used for molecular 
weight estimation and tracking during electrophoresis.  
 
3.4.2 Electroblotting  
Protein transfer was carried out on Amersham Hybond PDVF Blotting Membranes pore size 
0.45μm (Cat#10600023, GE Healthcare Life Sciences, Marlborough, Massachusetts, USA). 
Wet electroblotting was run at 25V for 90 minutes in 10% Methanol NuPAGE™ Transfer 
Buffer (20x stock, Cat#NP0006, InvitrogenTM) with NuPAGE™ Antioxidant (1000x stock, 
Cat#NP0005, Invitrogen™) at 4°C. 
 
3.4.3 Chemoluminescence 
Membranes were washed with PBS-Tween 0,1% (PBS-T) and blocked for 1 hour at room 
temperature (RT, ~22°C) in 5% milk (Non-fat dry milk, PBS-T), followed by an overnight 
incubation at 4°C with the primary antibody diluted in 5% milk. Next day, membranes were 
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washed three times for 5 minutes with PBS-T followed by 1h incubation with Horseradish 
Peroxidase (HRP)-conjugated secondary antibodies diluted in 5% milk. Membranes were 
washed again three times for 5 minutes with PBS-Tween 0,1%, and signals for protein bands 
were developed using a SuperSignal™ West Femto Maximum Sensitivity Substrate 
(Cat#34096, Thermo Scientific) in a ChemiDoc™ MP Imaging System (Cat#170-01402, Bio-
Rad). All incubations and washings were done under agitation (20 osc/min). β-actin was used 
as loading control. Antibodies used in Western blots are described in the Table 5. 
3.5 Cell Count in Lymphoid Organs  
Initially, spleens and thymi were isolated from mice and collected in a tube with 0.5mL PBS 
on ice. Then, the organs were weighted and transferred to petri dishes with 10mL of PBS. A 
plunger of a syringe was used to mash the tissue of the spleen and thymus to release cells into 
the PBS solution. The cell suspensions were filtrated through 40 μm Fisherbrand™ Sterile 
Cell Strainers (Cat#22-363-547, Fisher Scientific, Hampton, New Hampshire, USA) into 
50mL conical centrifuge tubes and centrifuged at 1200 rpm for 5 minutes at 4°C. Pellets were 
gently re-suspended in 1mL of Red Blood Cell (RBC) Lysis Buffer Hybri-Max™ 
(Cat#R7757, Sigma-Aldrich, St. Louis, Missouri, USA) at RT and left for 5 minutes to lyse 
RBCs. Cells were diluted with PBS to a final volume of 50mL. The cells were counted in a 
Countess II FL Automated Cell Counter (Cat#AMQAF1000, nvitrogenTM) using Trypan Blue 
Stain 0.4% (Cat#T10282, InvitrogenTM) and Countess Cell Counting Chamber Slides 
(Cat#C10228, InvitrogenTM). 
3.6 Tail Fibroblast (TF) Primary Cell Culture   
Whole tails from one-month old mice were collected in PBS on ice and transported to the 
laboratory for their respective processing. The tails were washed with 75% ethanol in 15mL 
conical centrifuge tubes for a minute. Immediately, mouse-tail skin was removed, and cut into 
approximately 4mm2 pieces with the help of micro-lance 3 Needles Cream 19g x 1.5 
(Cat#ND500, Becton Dickinson, Ireland) and carbon steel scalpel blades #22 (Cat#233-0028, 
Braun, Germany). Tail pieces were treated with 2mg/mL collagenase II (Cat#17101-015, 
Gibco by life technologies, USA) in Dulbecco’s Modified Eagle’s Medium high glucose 
(DMEM) (Cat#D6429, Sigma-Aldrich, United Kingdom) supplemented with 10% 
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concentration in volume/volume (v/v) Fetal Bovine Serum (FBS) (Cat#F7524, Sigma-
Aldrich, USA), 1% v/v L-glutamine solution (200mM) (Cat#G7513, Sigma-Aldrich, United 
Kingdom) and 1% v/v antibiotics (Penicilin/Streptomycin 10,000 U/mL (Cat#15140-122, 
Gibco, Life Technologies, USA)) for 24 h [37°C, 5% v/v CO2 incubator]. Next day, the tail 
pieces were washed with the same medium and gently pipetted up and down around 50 times 
and filtered through a 40-μm nylon cell strainer (Cat#22-363-547, Fisher Scientific). Filtered 
samples were centrifuged at 1200 rpm for 5 minutes at RT. Pellets were re-suspended in 
10mL of supplemented DMEM and plated in a 10cm culture dish for 24 h [37 °C, 5% v/v 
CO2 incubator]. At the third day, the medium was discarded and cells were washed with PBS 
and cultured in 10mL of supplemented DMEM at 37 °C, 5% v/v CO2 incubator.  
 
Cell culture was carried out in a laminar flow bench (KOJAIR®, Vilppula, Finland), which 
was sterilized with 75% ethanol before and after use. Cells were visualized using an inverted 
light microscope (Cat#AE31, Motic®, Germany). All plastics were purchased from VWR 
International (Norway). 
3.7 Proliferation assays 
Tail fibroblast (TF) cells were plated 5×104 cells/mL in triplicate in 6-well plates in 
supplemented DMEM and counted every 48 hours using 10µL Trypan Blue Stain 0.4% 
(Cat#T10282, InvitrogenTM) mixed with 10µL cells on CountessTM Cell Counting Chamber 
Slides (Cat#C10228, InvitrogenTM), and counted using the CountessTM II FL Automated Cell 
Counter (Cat#AMQAF1000, InvitrogenTM). Every 2 days, the medium was changed. Before 
counting, medium was discarded then washed with PBS and incubated with Trypsin-EDTA 
solution (Cat#T3924, Sigma-Aldrich, USA) for 20 minutes at 37°C, 5% v/v CO2 incubator. 
Fibroblast cells from the second or third passages were used for this assay. 
3.8 Telomere - Fluorescence in situ hybridization (T-
FISH) 
Fibroblasts from the second or third passages were used for telomere FISH assay. Fibroblasts 
were treated with 100ng/mL colcemid (Cat#1512-012, KaryoMAX® Colcemid solution; 
Gibco) for 6h [73, 76]. Then the cells were incubated in trypsin for 15 minutes and then 
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combined with the medium collected earlier. Next, cells were lysed in the hypotonic solution 
(75 mM KCl) at 37 °C for 20 min, then cells were fixed in methanol:acetic acid (3:1), and air 
dried on slides overnight for the metaphase analysis [73, 78]. Slides were digested with pepsin 
(1mg/mL) during 10 minutes at 37°C. Subsequently; slides were heated at 80°C for 3 minutes 
to denature DNA. Finally, telomeres were stained with a Cy3-labeled 
CCCTAACCCTAACCCTAA probe (PANAGENE, Yuseong-gu, Korea) in 70% formamide 
(Cat#F-9037, Sigma-Aldrich) at RT for 2 hours, washed, dehydrated and mounted with 
VECTASHIELD® MOUNTING MEDIUM with DAPI (#H-1200, Vector Laboratories, CA, 
USA). 
Chromosomal breaks were defined by the loss of telomere signal from both sister chromatids, 
whereas chromatid breaks by no telomere signal at one of the two sister chromatids or a clear 
lack of DAPI signal in the middle of one chromatid[79]. Metaphase images were captured 
using a Zeiss Laser TIRF3 microscope equipped with a charge-coupled device (CCD) camera 
and a 100× objective lens. 
3.9 Cell staining for Flow Cytometry 
Spleens and thymi were isolated in petri dishes with cold PBS-5% FBS (Cat#F7524, Sigma 
Life Science). The organs were mashed, filtrated, and centrifuged as previously described 
(Section 3.5). Pellets were re-suspended in 1mL of RBC lysis buffer Hybri-Max (Cat#R7757, 
Sigma-Aldrich) and incubated for 5 minutes at RT. Cells were washed with 10mL PBS-5% 
FBS and centrifuged at 1500 rpm for 5 minutes at 4°C. Pellets were re-suspended in 10ml 
PBS-5% FBS and a filtered second time through a 40μm cell strainer (Cat#22-363-547, 
Fisher Scientific). Cells were counted as previously described (Section 3.5).  
 
Cell suspensions were spun down and diluted with PBS-2% FBS to get a final concentration 
of 2.5x107 cells/mL. Each sample consisted of 2.5x106 cells. The cells were blocked for 15 
minutes (RT) with Mouse BD Fc Block™ (Cat#553141, BD Biosciences, New Jersey, USA) 
diluted 50x in PBS-2% FBS. The samples were then incubated with fluorochrome-conjugated 
antibodies diluted in PBS-2% FBS for 30 minutes in darkness, 4°C. The cells were washed 
and spun down (1500rpm, 5 minutes, 4°C) two times with 500μL PBS-2% FBS, before 
transfer intro Falcon™ Round-bottom polystyrene tubes (Cat#352054, Corning™, New 
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York, USA). Single-stained CD3/CD19/CD4/CD8 BD™ CompBead Anti-Rat and Anti-
Hamster Ig κ particles (Cat#552845, BD Biosciences) were used for compensation. 
Unstained splenocytes/thymocytes were used as controls. The samples were run in a BD 
FACSCanto™ flow cytometer using the BD FACSDiva™ software, and the data was further 
analyzed using the FlowJo® V10 software (FlowJo LLC, New Jersey, USA). Antibodies 
used in flow cytometry are described in the Table 6. 
3.10 Xlf.Paxx.Trp53 Breeding  
Initially, heterozygous Xlf mice [53] were crossed with our Paxx mouse model[58]. Xlf+/- 
Paxx+/- mice were then crossed with Trp53+/- mice[77] to obtain suitable genotypes for further 
breeding. Later, Xlf+/-Paxx+/-Trp53+/- mice were crossed with each other.  
 











Information about antibodies used for Western blot and flow cytometry assays is presented in 
Tables 5 and 6, respectively. 
 
Table 5: Antibodies used in Western blots. The table summarizes antibody host and target, used dilutions, 




Dilution Catalogue # Supplier 
Anti-XLF Rabbit Anti- 
Human, 
polyclonal 




Anti-PAXX Rabbit Anti- 
Human, 
polyclonal 
1:250 NBP1-94172 NovusBio, 
Littleton, CO, 
USA, 
Anti-β-actin  Mouse Anti- 
Human, 
monoclonal 






















Table 6: Antibodies used in flow cytometry. The table indicates antibody fluorochrome conjugate, host and 






Dilution Catalogue # Supplier 












PE-Cy7 Rat Anti- 
Mouse, 
monoclonal 









PE-Cy5 Rat Anti- 
Mouse, 
monoclonal 
1:100 553034 BDBiosciences 
Anti-CD19  Pe-Cy7 Rat Anti- 
Mouse 
 
1:100 115520  Biolegend 
3.12 Statistics  
GraphPad Prism 8 (La Jolla, California, USA) was used for statistical analysis of body weight, 
cell counts, spleen weight, thymus weight, and proportions of B and T lymphocytes among 
the different genotypes. A one-way ANOVA was performed for all groups of variables.  
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4. RESULTS 
4.1 Genotyping  
DNA extracted from murine ear samples was used. All mice used for experiments, such as 
organ isolation, cell counting, Western blot analysis, flow cytometry, T-FISH, and breeding, 
were characterized genotyping using PCR and gel electrophoresis. Xlf-/-Paxx-/-Trp53+(-)/- mice 
were evaluated by PCR twice, before and after the use of the samples. Examples of all PCR 
assays performed during this project are presented in Figure 10; A) Xlf WT allele, B) Xlf 
mutant allele, C) Paxx WT and mutant alleles, D) Ku80 WT and mutant alleles, E) Trp53 WT 
allele, F) Trp53 mutant allele, G) Dna-pkcs WT allele and H) Dna-pkcs mutant allele. For 
reliability, positive (WT allele), negative (knockout allele), and dH2O controls were used in 




Figure 10: Examples of PCR analysis for Xlf, Paxx, Ku80, Trp53 and Dna-pkcs, with positive (“+”, WT 
allele), negative (“-”, mutant allele) and blank samples (H2O) as controls. A) Xlf WT. Bands correspond to the 
Xlf WT allele (650bp). B) Xlf mutant. Bands correspond to the Xlf mutant allele (950bp). C) Paxx WT and 
mutant. The upper band corresponds to the WT allele (965bp) and the lower band corresponds to the mutant 
allele (either 329, 312, or 295bp, due to three independent Paxx knockout sub-lines used). D) Ku80 WT and 
mutant. Samples with an amplified WT allele (400bp) are shown to the left, and samples with an amplified 
mutant allele (320bp) are shown to the right. E) Trp53 WT. Bands correspond to the Trp53 WT allele 
(321bp). F) Trp53 mutant. Bands correspond to the Trp53 mutant allele (150bp). G) Dna-pkcs WT. Bands 
correspond to the Dna-pkcs WT allele (250bp). H) Dna-pkcs mutant. Bands correspond to the Dna-pkcs 
mutant allele (427bp).  
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Figure 11: Example of an Xlf-/- Paxx-/- Trp53+/- mouse identified by PCR (Sample number 33 is highlighted in 
the Figures). A) Xlf WT and mutant. Sample 33 only has a band corresponding to the mutant allele (genotype 
Xlf-/-). B) Paxx WT and mutant. Sample 33 only has the lower band corresponding to the mutant allele 
(genotype Paxx-/-). C) Trp53 WT and mutant. Sample 33 has both bands corresponding to WT and mutant 




4.2 Xlf Paxx Trp53 Breeding 
According to the previous results, double deficiency of XLF and PAXX leads to an 
embryonic lethality in mice[56, 57, 59]. I proposed that inactivation of one or two alleles of 
Trp53 could rescue the lethality of this combined deficiency in mice. My samples were 
generated from the crossbreeding of Xlf-/- Paxx+/- Trp53+/- mice. 
 
A total of 120 mice were genotyped. The distribution of the analyzed and expected mice are 
presented in the Table 7. No Xlf-/-Paxx-/- Trp53+/+ mice were found due to the embryonic 
lethality. 
 
Table 7: Inactivation of Trp53 rescues synthetic lethality between Xlf and Paxx in mice. The number of thirty-
day-old mice (P30) of the indicated genotypes. Mendelian distribution (Expected) is provided in the third 
column. Both parents possessed the Xlf-/-Paxx+/-Trp53+/- genotype. In total, 120 mice were screened. Numbers 
























Total 120 120 
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4.3 Protein expression in Tail Fibroblasts (TF) 
Samples previously identified by PCR as Xlf-/-, Paxx-/- and Xlf-/-Paxx-/- Trp53+(-)/- mice were 
randomly chosen to confirm the absence of their corresponding proteins by Western blots. 
Expression of XLF and PAXX proteins was tested using TF primary cell culture extract. 
 
Xlf knockout mice were confirmed by the lack of the XLF (37kDa) band, and Paxx knockout 
mice were confirmed by the lack of the PAXX (22kDa) band. There were neither XLF nor 
PAXX corresponding bands in Xlf-/-Paxx-/- Trp53+(-)/- mice (Figure 12).  
 
β-actin (42kDa) protein was used as a loading control to normalize the protein expression. 
 
 
Figure 12: Western blots using anti-XLF (37kDa band) and anti-PAXX (22kDa band) immunoglobulins in 
Xlf-/-, Paxx-/-, Xlf-/-Paxx-/-Trp53+(-)/- and WT samples. A) Detection of XLF in murine tail fibroblasts. B) 
Detection of PAXX in murine tail fibroblasts. Double knockouts were confirmed by the absence of both XLF 








4.4 Growth and Immune system development in Xlf-/-
Paxx-/- Trp53+(-)/- mice 
 
A total of 41 mice was used to characterize the body weight, size of spleen, thymus, and the 
number of cells, which reside in the spleens and thymi among positive controls (samples with 
WT, Xlf and Paxx genes, Xlf+/+ Paxx+/+) (n=6), Xlf-/- (n=16), Paxx-/- (n=9) and Xlf-/- Paxx-/- 
Trp53+(-)/- (n=10) mice. Mice with double knockout of Xlf and Paxx and partial or total Trp53 
knockout were grouped. No difference among these mice was identified.  
Xlf-/- Paxx-/- Trp53+(-)/- mice were significantly smaller than age-matched Xlf+/+ Paxx+/+, and 
single knockout controls Xlf-/- and Paxx-/- (p ≤ 0.0001) (Figure 13 A and B). Furthermore, Xlf-
/- Paxx-/- Trp53+(-)/- possessed reduced size of spleens and thymi (Figure 13 C, D and E) and 
severe lymphocytopenia compared to Xlf+/+ Paxx+/+, Xlf-/- and Paxx-/- controls (p ≤ 0.0001) 
(Figure 13 F and G). Apparently, the small quantity of splenocytes and thymocytes 
corresponds to background levels.  
In addition, Xlf-/- Paxx-/- Trp53+(-)/- mice were viable up to 60 days and died for unknown 
reasons. No tumors were detected in these mice during the indicated period of time. Males 





Figure 13: Growth and immune system development of Xlf-/- Paxx-/- Trp53+(-)/- mice. (A) Example of thirty-
day-old Xlf-/- Paxx-/- Trp53+/- and Xlf-/- Trp53+/- female littermates. (B) The average weight of thirty-day-old 
mice in grams. (C) Spleens (left) and thymi (right) isolated from Xlf-/- Trp53+/- and Xlf-/- Paxx-/- Trp53+/- mice. 
The weight of spleens (D) and thymi (E) isolated from thirty-day-old mice of indicated genotypes. Count of 
splenocytes (F) and thymocytes (G) isolated from thirty-day-old mice of indicated genotypes.  
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4.5 Frequencies and number of B and T cells in 
lymphoid organs of Xlf-/-Paxx-/- Trp53+/- mice 
The splenocytes and thymocytes were analyzed by flow cytometry in order to find if the 
combined inactivation of Xlf and Paxx resulted in mice developing B and T lymphocytes. 
Xlf-/- Paxx-/- Trp53+/- (n=3) mice were compared to the single knockouts Xlf-/- (n=4) and Paxx-
/- (n=4), in addition to Xlf+/+ Paxx+/+ (n=3) and Dna-pkcs-/- mice (n=4) used as controls [68].  
Isolated murine splenocytes of indicated genotypes were stained with Anti-C19 and Anti-CD3 
antibodies to determine the proportion of B and T cells, respectively. Furthermore, I used 
Anti-CD4 and Anti-CD8 antibodies to identify CD4+ and CD8+ single and double positive T 
cells in the spleens and thymi. The mice used in this analyzes were 5 to 8 weeks old. 
CD19+ and CD3+ (B and T cells, respectively) frequency and count are presented in the Table 
8. Examples from flow cytometry analysis of Anti-CD3/Anti-CD19 stained splenocytes are 
presented in the Figure 14.A. There was significant difference in splenic B and T cells (Figure 
14.B.1 and 14.C.1) among Xlf-/- Paxx-/- Trp53+/- compared to controls mice. The total number 








Table 8: Frequencies (%) and count of B and T cells among Xlf+/+ Paxx+/+, , Xlf-/-, Paxx-/-, Xlf-/-Paxx-/-Trp53+/- 
and Dna-pkcs-/-  mice analysed by flow cytometry. Molecular markers CD3+ and CD19+ correspond to T and B 
cells, respectively. RBCs were lysed prior to flow cytometry analysis, therefore, they were not taken into 
account.  
     
Figure 14: Splenic B and T cells in Xlf+/+ Paxx+/+, Xlf-/-, Paxx-/-, Xlf-/-Paxx-/-Trp53+/- and Dna-pkcs-/- mice. A) 
Flow cytometry analysis of splenocytes stained with Anti-CD3 (T cell marker) and Anti-CD19 (B cell 
marker), frequencies (%) are indicated. B.1) Comparison in CD19 positive splenocytes (%). B.2) Total 
number of B cells in each genotype. C.1) Comparison in CD3 positive splenocytes (%). C.2) Total number of 
T cells in each genotype. Dna-pkcs-/- mice were used as negative control. Minimum n=3. Not significant (NS) 
= p > 0.05, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001 and **** = p ≤ 0.0001. 
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Frequencies and count of CD4+ and CD8+ T splenocytes are presented in the Table 9. A 
representative Figure from flow cytometry analysis of Anti-CD4/Anti-CD8 stained cells is 
presented in the Figure 15.A.   
 
Xlf-/- Paxx-/- Trp53+/- mice showed a significant reduction in the proportion of T helper and T 
cytotoxic cells compared to Xlf+/+ Paxx+/+, Xlf-/- and Paxx-/- mice (Figure 15.B.1 and 15.C.1). 
Nevertheless, Xlf-/- Paxx-/- Trp53+/- had a significant increase of CD8+ subset cells compared 
to negative control mice lacking DNA-PKcs. The number of CD4+ and CD8+ T cells in the 
spleen is shown in the Figure 15.B.2 and 15.C.2, respectively. 
 
Table 9: Frequencies (%)  and number of CD4+, TH cells and CD8+, TC cells among Xlf+/+ Paxx+/+, Xlf-/-, 
Paxx-/-, Xlf-/-Paxx-/-Trp53+/- and Dna-pkcs-/- mice analysed by flow cytometry. RBCs were lysed prior to flow 






Figure 15: Splenic CD4/CD8 T cells in Xlf+/+ Paxx+/+, Xlf-/-, Paxx-/-, Xlf-/-Paxx-/-Trp53+/- and Dna-pkcs-/- mice. 
A) Flow cytometry analysis of splenocytes stained with Anti-CD4 (T helper cells) and Anti-CD8 (T 
cytotoxic), frequencies (%) are indicated. B.1) Comparison in CD4 positive splenocytes (%). B.2) Total 
number of TH cells in each genotype. C.1) Comparison in CD8 positive splenocytes (%). C.2) Total number of 
TC cells in each genotype. TH: T helper cells. TC: T cytotoxic cells. Dna-pkcs-/- were used as negative control. 




Thymic cell frequencies and count of CD4+CD8+, CD4+ and CD8+ T cells, are presented in 
the Table 10. A representative Figure from flow cytometry analysis of Anti-CD4/Anti-CD8 
stained thymocytes is presented in the Figure 16.A.   
 
Xlf-/- Paxx-/- Trp53+/- mice had a significant reduction in the proportion of CD4 T cells 
compared to Xlf+/+ Paxx+/+, Xlf-/- and Paxx-/- mice (Figure 16.B.1). However, deficiency for 
XLF and PAXX resulted in significant increase of TC cell proportion compared to Dna-pkcs
-/- 
mice and no difference compared to Xlf+/+ Paxx+/+, Xlf-/- and Paxx-/- mice (Figure 16.C.1). 
Additionally, there was a significant reduction of double positive (CD4+ CD8+) thymocytes 
among Xlf-/- Paxx-/- Trp53+/- compared to Xlf+/+ Paxx+/+ and Paxx-/- mice. Moreover, mice with 
combined deficiency for XLF and PAXX possessed a significant increase of DP cells 
compared to the negative controls lacking DNA-PKcs (Figure 16.D.1). The number of CD4+, 
CD8+ and CD4+ CD8+ cells is shown in the Figures 16.B.2, 16.C.2 and 16.D.2, respectively. 
Table 10: Frequencies (%)  and number of thymic DP and SP T cells among Xlf+/+ Paxx+/+, Xlf-/-, Paxx-/-, Xlf-/-
Paxx/-Trp53+/- and Dna-pkcs-/- mice analysed by flow cytometry. CD4+CD8+, double positive T cells; CD4+, TH 








Figure 16: Thymic CD4/CD8 T cells in Xlf+/+ Paxx+/+, Xlf-/-, Paxx-/-, Xlf-/-Paxx-/-Trp53+/- and Dna-pkcs-/- mice. 
A) Flow cytometry analysis of thymocytes stained with Anti-CD4 (T helper cells) and Anti-CD8 (T cytotoxic). 
Frequencies of correspondent cell types (%) are indicated. B.1) CD4 positive splenocytes (%). B.2) Total 
number of TH cells in each genotype. C.1) CD8 positive splenocytes (%). C.2) Total number of TC cells in 
each genotype. D.1) CD4CD8 double positive splenocytes (%). D.2) Total number of double positive (DP) T 
cells. DP: CD4+CD8+T cells. TH: T helper cells. TC: T cytotoxic cells. Dna-pkcs-/- were used as negative 
control. Minimum n=3. Not significant (NS) = p > 0.05, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001 and 






4.6 Proliferation of Tail Fibroblasts (TF) 
In order to investigate the proliferative potential of the Xlf-/- Paxx-/- Trp53+/- cells, they were 
compared against the single knockouts Xlf-/- and Paxx-/-, in addition to Xlf+/+ Paxx+/+ controls 
(same samples as used in the Section 4.5). Three animals of each genotype were selected, and 
5×104 cells/mL were cultured per sample in triplicate. TFs were counted every 2 days from 
day 0 until day 6 (Figure 17).   
Xlf-/- Paxx-/- Trp53+/- cells were compared to Xlf+/+ Paxx+/+ samples and showed significant 
difference in the cell proliferation rate. In the second, fourth and sixth day of experiment, the 
respective p-values were 0,0025; 0,0001 and < 0,0001.  
Additionally, Xlf-/- Paxx-/- Trp53+/- mice displayed a significant reduction in number of TF cells 
compared to Xlf-/- mice. In the second, fourth and sixth day of experiment, the respective p-
values were 0,0004; 0,0002 and < 0,0001.  
Finally, Xlf-/- Paxx-/- Trp53+/- TF proliferation rate was significantly different when compared 
to Paxx-/- TFs. In the second, fourth and sixth days of evaluation, the respective p-values were 
0,0013; 0,001 and 0,0003.  









Figure 17: Proliferation of tail fibroblast (TF) cells from Xlf+/+ Paxx+/+, Xlf-/-, Paxx-/- and Xlf-/- Paxx-/- Trp53+/- 
mice. A graph represents a summary of three experiments in triplicates. Control+ mice are Xlf+/+ Paxx+/+. 
 
Table 11: A summary of the statistical analyzes by one-way ANOVA of TFs proliferation. Xlf+/+ Paxx+/+ vs 
Xlf-/- Paxx-/- Trp53+/-, Xlf-/- vs Xlf-/- Paxx-/- Trp53+/-, and Paxx-/- vs Xlf-/- Paxx-/- Trp53+/- mice. Not significant 
(NS) = p > 0.05, * = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001 and **** = p ≤ 0.0001. 
 Control+ vs 
Xlf-/- Paxx-/- Trp53+/- 
Xlf-/- vs 
Xlf-/- Paxx-/- Trp53+/- 
Paxx-/- vs 
Xlf-/- Paxx-/- Trp53+/- 
Day 2 ** *** ** 
Day 4 *** *** *** 






4.7 Genomic stability evaluated by T-FISH 
Telomere Fluorescence in situ hybridization (T-FISH) assays was chosen to identify genomic 
stability at the chromosomal level. 
The chromosomes and telomeres were stained with DAPI (a fluorescent stain that binds 
strongly to adenine–thymine rich regions in DNA) and Cy3-labeled (an orange-fluorescent) 
CCCTAACCCTAACCCTAA probe, respectively. Chromosomal breaks were defined by the 
loss of telomere signal from both sister chromatids, whereas chromatid breaks were defined 
by no telomere signal at one of the two sister chromatids or a clear lack of DAPI signal in the 
middle of one chromatid (Figure 18). 
Figure 18: Genomic instability in murine tail fibroblasts. A) Representative scheme of intact and abnormal 
chromosomes, including chromosome and chromatid breaks. B) Examples from our samples of intact and 






Xlf-/-Paxx-/-Trp53+/- and Xlf-/-Paxx-/-Trp53-/- TFs were selected in order to investigate the 
genomic stability using T-FISH assays. However, with the small quantity of TFs after the 
second or third passages from Xlf-/-Paxx-/-Trp53+/- samples it was not possible to continue this 
experiment, whereas, Xlf-/-Paxx-/-Trp53-/- TFs after second or third passage had enough cells 
for T-FISH assays.  
Furthermore, some changes in the technique were necessary with the purpose of optimizing 
the method for the future experiments, for instance: 
1. Primary tail fibroblasts from mice have to be exposed to trypsin between 15-20 
minutes instead of 5 minutes at 37°C to detach from the surface. Or higher 
concentration of trypsin can be used for shorter time. 
2. Five to six petri dishes (1x106 cells per dish) in a final volume of 10 ml medium must 
be used to collect enough samples for analyzes. 
3. Increased incubation time in the hypotonic solution (75 mM KCl) at 37 °C from 15 to 
20 minutes to obtain more metaphases for analyzes.  
All these changes led to improved results. 
Table 12: Summary of genomic instability in Xlf+/+ Paxx+/+, Xlf-/-, Paxx-/- and Xlf-/- Paxx-/- Trp53-/- mice. 
Number (n) and proportion (%) of metaphases with detected chromosomal or chromatid breaks in fibroblasts 




5.1 Deficiency for Trp53 partially rescues embryonic 
lethality of Xlf-/-Paxx-/- mice  
Inactivation of individual Xlf, Dna-pkcs, Mri or Paxx genes resulted in no obvious defect in 
the neurodevelopment, nevertheless, combined inactivation of Xlf and Dna-pkcs (Xlf−/− Dna-
pkcs−/−) [73], Xlf and Mri (Xlf−/−Mri−/−) [35] or Xlf and Paxx (Xlf−/−Paxx−/−) [56, 57, 59, 65], 
resulted in embryonic lethality likely due to severe neuronal apoptosis in murine brain during 
embryonic development. Core NHEJ knockout mouse models, Xrcc4−/− and Lig4−/−, also 
possess late embryonic lethality (at day E.15.5). However, deletion or haploinsufficiency for 
Trp53 partially rescued embryonic lethality of Xrcc4−/− [72, 75] and Lig4−/− [71, 80] mice 
likely due to reduced apoptosis in the central nervous system. Similar results were found in 
Xlf−/− Dna-pkcs−/− mice with haploinsufficiency for Trp53 [65, 76]. 
It is suggested that XLF plays a role in the neurodevelopment, while it is compensated by 
other factors, e.g. accessory NHEJ proteins DNA-PKcs, Mri and PAXX. In addition, XLF 
and PAXX are structural homologues. Moreover, XLF is a conserved protein in all 
eukaryotes, while PAXX is absent in most invertebrates and in yeast [76], proposing that 
PAXX has evolved to participate in resolving more complex breaks in higher eukaryotes.  
During this project, one hundred and twenty mice from the crossbreeding of Xlf-/- Paxx+/- 
Trp53+/- mice were genotyped and characterized. No Xlf-/- Paxx-/- Trp53+/+ mouse was found. 
Nevertheless, I discovered that inactivation of one or both alleles of Trp53 partially rescues 
the lethality of Xlf−/−Paxx−/− mice, even more interesting, their proportions are similar to the 
expected mendelian distribution (Table 7 and [65]).
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Furthermore, Xlf-/- Paxx-/- double deficient mice showed no detectable XLF and PAXX 
protein in tail fibroblasts (Figure 12) confirming the inactivation of both Xlf and Paxx alleles. 
TRP53 (p53) expression was not evaluated because its respective antibody was not available.  
 
Additionally, Xlf-/- Paxx-/- Trp53+/- and Xlf-/- Paxx-/- Trp53-/- mice were viable up to 60 days and 
died for unknown reasons, nonetheless, it is possible that the early lethality of these mice 

























5.2 Growth and immune system development 
 
PAXX and XLF are not essential for V(D)J recombination due to compensatory mechanisms 
[53, 55-57, 59, 62, 64, 65, 81], and a combined inactivation of these proteins in mice leads to 
lethality [56, 57, 59]. Xlf−/− mice possess rearranges in V, D, and J segments of pro-B cells 
and DN thymocytes at nearly WT [52, 53], carrying out to the development of B and T cells, 
respectively. Furthermore, Paxx−/− mice have similar ratios of B and T cell populations when 
compared to positive controls [56-59]. Similar to my results, where single knockout mice 
(Xlf−/− and Paxx−/−) show no significant difference among them and when compared to Xlf+/+ 
Paxx+/+ mice. 
Inactivation of one or two alleles of Trp53 results in a partial rescue of lethality in 
Xlf−/−Paxx−/− mice. It could be due to a reduced cellular apoptosis, which allows postnatal 
survival. As in the case of Lig4-/- Trp53+(-)/- and Xrcc4-/- Trp53+(-)/- mice, where the embryonic 
lethality is rescued, showing a reduction of the neuronal apoptosis, and premature senescence 
phenotypes, and no lymphocyte development [75].  
Furthermore, our Xlf−/−Paxx−/− Trp53+(-)/- deficient mice possess smaller body size, spleen and 
thymus weight when compared to single knockouts and Xlf+/+ Paxx+/+ controls. Additionally, 
they show a severe reduction of the lymphocytes both in spleens and in thymi. Ku80 deficient 
mice have a reduction of the body weight by around 50% when compared to WT age and 
gender-matched mice. Moreover, Ku80-/- mice have only some residual cells in spleens and 
thymi, which correspond to progenitor T cells in the thymi, and other populations of immune 
cells in the spleens [69]. Data not shown here, but recently published by us, Castaneda-
Zegarra, S., et al. [65] (Appendix C), that Xlf-/- Paxx-/- Trp53+(-)/- mice have similar body size, 
spleens/thymi weight and number of splenocytes and thymocytes when compared to Ku80-/- 




5.3 B and T cell frequencies in limphoid organs 
B and T, splenocytes and thymocytes from Xlf-/- Paxx-/- Trp53+/- mice were analysed by FACS 
in order to identify and quantify accurately the frequency and number of cell types. Only three 
Xlf-/- Paxx-/- Trp53+/- mice were available and no triple knockouts was ready for use at the 
time of the experiments. To increasing the statistical power, additional Xlf-/- Paxx-/- Trp53+/- 
mice will be analysed in the future. 
Inactivation of one Trp53 allele does not affect the development of lymphocytes in WT mice 
[39, 71]. It allows us to study an accurate in vivo impact of XLF-PAXX deficiency. Xlf-/- 
Paxx-/- Trp53+/- mice were compared to Xlf+/+ Paxx+/+, Xlf−/− and Paxx−/− controls, as well as 
Dna-pkcs−/− (control-) mice. DNA-PKcs deficient mice have a SCID phenotype and, alike 
Ku80-/-, they have just some residual cells in spleens and thymi. 
RBCs, mature B and T cells and other immune cells inhabit the spleen. While in the thymus, 
immature and mature T cells reside. Mature T cells, T helpers (CD4+) and cytotoxic T cells 
(CD8+) leave from the thymus and pass through the circulation to the lymph nodes or the 
spleen. In the spleen, B lymphocytes maturate with the assistance of CD4+ cells upon 
interaction with foreign antigens.  
Xlf-/- Paxx-/- Trp53+/- mice possess no B splenocytes, similar to Dna-pkcs−/− controls. 
Although Xlf-/- Paxx-/- Trp53+/- mice did not show difference in splenic T cell frequency when 
compared to negative control (Dna-pkcs deficient) mice, its T-cell frequency is three times 
higher than in Dna-pkcs−/− and three time lower than in Xlf+/+ Paxx+/+ mice, respectively. 
Ouyang, H., et al. [82], similarly, showed that it was not possible to identify B cells (CD19+), 
but there were T cells (CD3+) in Ku70-/- splenocytes. Furthermore, Ku70-/- mice possessed 
similar body weight when compared to Ku80-/- and their spleens were disproportionately 
smaller, by 5–10-folds, relative to WT and heterozygous controls. Therefore, in vivo XLF 
and PAXX are required for DNA repair, but possibly there are alternative pathways which 
would be relevant for T Cell Antigen Receptor Gene Recombination, as it is in the case of 
Ku70-/- mice [74]. 
Both CD4+ and CD8+ are present in the spleens of Xlf-/- Paxx-/- Trp53+/- mice, certainly in 
lower proportion with respect to Xlf+/+ Paxx+/+, Xlf−/− and Paxx−/− samples. However, and 
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surprisingly, Xlf-/- Paxx-/- Trp53+/- possessed approximately two-thirds of normal CD8+ cell 
frequency. Furthermore, to our surprise, Xlf-/- Paxx-/- Trp53+/- mice had almost normal 
frequencies of DP T cells (CD4+CD8+) (~ 75%) in the thymi. It implies that DP T cell 
frequency of Xlf-/- Paxx-/- Trp53+/- samples compared to the rest of genotypes is almost 
identical, obviating the slight difference in comparison to Xlf+/+ Paxx+/+ and Paxx−/− mice. 
This difference might be explained by the small used sample of Xlf-/- Paxx-/- Trp53+/- (n=3) 
mice.  
My data show that in the absence of XLF and PAXX, T cells are able to develop to DP in the 
thymus, even though the thymus is also disproportionately smaller and contains around 40-
fold fewer CD4+CD8+ lymphocytes compared to the single knockouts and Xlf+/+ Paxx+/+ 
mice. SP T cells (CD4+ or CD8+) are originated from DP T cells in the thymus. The frequency 
of CD4+ T cells in our Xlf-/- Paxx-/- Trp53+/- mice was similar to the negative controls (Dna-
pkcs-deficient). Nevertheless, strikingly, the CD8+ cell proportion was very much similar to 
the Xlf+/+ Paxx+/+, Xlf−/− and Paxx−/− samples.  
Finally, the frequency of CD8+ cells in both the spleen and thymus of Xlf-/- Paxx-/- Trp53+/- 
mice is the double (2:1) regarding to the CD4+ cell frequency, even when the normal 
frequency is the opposite (1:2) in the thymus [25]. It leads us to hypothesize that XLF and 
PAXX play a role in the development of T lymphocytes from DP T cells to CD4+ and CD8+ T 








5.4 Proliferation of TFs  
Xlf-/- Paxx-/- Trp53+/- TFs were chosen in order to investigate the cell proliferation, and Xlf+/+ 
Paxx+/+, Xlf-/- and Paxx-/- cells were used as controls. No Xlf-/- Paxx-/- Trp53-/- mouse was used 
given that complete inactivation of Trp53 carries out to a significant increase of cell 
proliferation due to reduced apoptosis [71, 83, 84].  
Xlf-/- Paxx-/- Trp53+/- TFs show reduced proliferation in the whole experiment compared to 
single knockouts and positive controls. Likely, in the absence of the accessory factors XLF 
and PAXX, DSBs cannot be repaired by C-NHEJ and the partial presence of Trp53 would 
lead a significant proportion of cells to apoptosis. Furthermore, it has been reported that p53 
restrains DSBs repair via homologous recombination while promoting non-homologous end 
joining [85]. 
No negative controls lacking NHEJ pathway (e.g., Ku70- or Ku80- deficient cells) were 
available at the time of the experimentation; however, it would be interesting to compare 










We were able to rescue the lethality of XLF-PAXX deficient mice by inactivating one or both 
alleles of Trp53. With this, we confirmed that synthetic lethality between Xlf and Paxx is p53-
dependent.  
In addition, Xlf-/-Paxx-/-Trp53+(-)/- mice differ phenotypically from Xlf-/- and Paxx-/- knockout 
mice resembling Ku80-/- and Ku70-/- mice. Moreover, Xlf-/-Paxx-/-Trp53+(-)/- mice possess 
reduced body size, spleen and thymus weight, as well as splenocytes and thymocytes count.  
Furthermore, flow cytometry analysis of splenocytes and thymocytes isolated from Xlf-/-Paxx-/-
Trp53+(-)/- mice revealed presence of CD4+ and CD8+ T cells and an almost normal frequency 
of CD4+CD8+ T cells in the thymi. Nevertheless, and surprisingly, this new mouse model has 
a frequency of CD8+ T cells similar to positive and single knockout controls both in the 
spleens and thymi. Whereby we can conclude that even when there is a small quantity of SP T 
cells, CD4+and CD8+ T cells are present in less or normal proportion (%), respectively. We 
also found that Xlf-/-Paxx-/-Trp53+(-)/- SP T cells can be originated in the thymus and moreover, 
they can migrate to the spleen. 
Additionally, based on our findings, the proliferative power of Xlf-/-Paxx-/-Trp53+/- cells is 
significantly less when compared to the single knockouts and WT mice.  
Finally, it was possible to optimize the Telomere Fluorescence in situ hybridization (T-FISH) 
technique, which will be used later to identify genomic stability at the chromosomal level in 





5.6 Future directions 
With the availability of this new mouse model (Xlf-/-Paxx-/-Trp53+(-)/-), it is possible to 
characterize mice lacking both XLF and PAXX. In the direction to our obtained results, it 
would be interesting in a near future to focus on the following aims: 
1. To complete a statistically significant sample to evaluate them by T-FISH assay. 
Around 250 metaphases and n=5 would be a good amount to analyse. It would 
show us the levels of genomic instability in Xlf-/-Paxx-/-Trp53+(-)/- mice. 
2. To analyse immature B and T cells in the bone marrow of Xlf-/-Paxx-/-Trp53+(-)/- 
mice. It would provide us enough data to conclude on the lymphocytic 
development.  
3. A new and interesting approach is to investigate the possible participation of XLF 
and PAXX in the positive selection from DP T cells (CD4+CD8+) to SP T cells 





1. Schultz, K.T. and F. Grieder, Structure and function of the immune system. Toxicol 
Pathol, 1987. 15(3): p. 262-4. 
2. Yatim, K.M. and F.G. Lakkis, A brief journey through the immune system. Clin J Am 
Soc Nephrol, 2015. 10(7): p. 1274-81. 
3. Parkin, J. and B. Cohen, An overview of the immune system. Lancet, 2001. 
357(9270): p. 1777-89. 
4. Tosi, M.F., Innate immune responses to infection. J Allergy Clin Immunol, 2005. 
116(2): p. 241-9; quiz 250. 
5. Dempsey, P.W., S.A. Vaidya, and G. Cheng, The art of war: Innate and adaptive 
immune responses. Cell Mol Life Sci, 2003. 60(12): p. 2604-21. 
6. Kindt, T., R. Goldsby, and B. Osborne, Kuby Immunology 6th ed, ed. W.H.F.a. 
Company. 2006. 
7. Bonilla, F.A. and H.C. Oettgen, Adaptive immunity. J Allergy Clin Immunol, 2010. 
125(2 Suppl 2): p. S33-40. 
8. Boehm, T., Design principles of adaptive immune systems. Nat Rev Immunol, 2011. 
11(5): p. 307-17. 
9. Fuxa, M. and J.A. Skok, Transcriptional regulation in early B cell development. Curr 
Opin Immunol, 2007. 19(2): p. 129-36. 
10. LeBien, T.W. and T.F. Tedder, B lymphocytes: how they develop and function. 
Blood, 2008. 112(5): p. 1570-80. 
11. Takahama, Y., Journey through the thymus: stromal guides for T-cell development 
and selection. Nat Rev Immunol, 2006. 6(2): p. 127-35. 
12. Hedrick, S.M., Thymus lineage commitment: a single switch. Immunity, 2008. 28(3): 
p. 297-9. 
13. Lin, W.C. and S. Desiderio, Cell cycle regulation of V(D)J recombination-activating 
protein RAG-2. Proc Natl Acad Sci U S A, 1994. 91(7): p. 2733-7. 
14. Roth, D.B., Restraining the V(D)J recombinase. Nat Rev Immunol, 2003. 3(8): p. 
656-66. 
15. Malu, S., et al., Role of non-homologous end joining in V(D)J recombination. 
Immunol Res, 2012. 54(1-3): p. 233-46. 
16. Schatz, D.G. and Y. Ji, Recombination centres and the orchestration of V(D)J 
recombination. Nat Rev Immunol, 2011. 11(4): p. 251-63. 
17. Montecino-Rodriguez, E. and K. Dorshkind, B-1 B cell development in the fetus and 
adult. Immunity, 2012. 36(1): p. 13-21. 
18. LeBien, T.W., Fates of human B-cell precursors. Blood, 2000. 96(1): p. 9-23. 
19. Hardy, R.R., P.W. Kincade, and K. Dorshkind, The protean nature of cells in the B 
lymphocyte lineage. Immunity, 2007. 26(6): p. 703-14. 
20. Pieper, K., B. Grimbacher, and H. Eibel, B-cell biology and development. J Allergy 
Clin Immunol, 2013. 131(4): p. 959-71. 
21. Wang, K., G. Wei, and D. Liu, CD19: a biomarker for B cell development, 
lymphoma diagnosis and therapy. Exp Hematol Oncol, 2012. 1(1): p. 36. 
22. Parham, P., The Immune System. 3rd ed. 2009: Garland Science. 
23. Holmes, M.L., C. Pridans, and S.L. Nutt, The regulation of the B-cell gene 
expression programme by Pax5. Immunol Cell Biol, 2008. 86(1): p. 47-53. 
 66 
24. Matos, T.R., M.A. de Rie, and M.B.M. Teunissen, Research Techniques Made 
Simple: High-Throughput Sequencing of the T-Cell Receptor. J Invest Dermatol, 
2017. 137(6): p. e131-e138. 
25. Kuo, T.C. and M.S. Schlissel, Mechanisms controlling expression of the RAG locus 
during lymphocyte development. Curr Opin Immunol, 2009. 21(2): p. 173-8. 
26. Immunology, B.S.f. T-cell development in thymus. 2019; Available from: 
https://www.immunology.org/public-information/bitesized-immunology/immune-
development/t-cell-development-in-thymus. 
27. Bio-Rad, Cell frequency by flow citometry. https://www.bio-rad-antibodies.com/flow-
cytometry-cell-frequency.html#%E2%80%8BMurine, 2017. 
28. Cannan, W.J. and D.S. Pederson, Mechanisms and Consequences of Double-Strand 
DNA Break Formation in Chromatin. J Cell Physiol, 2016. 231(1): p. 3-14. 
29. Sancar, A., et al., Molecular mechanisms of mammalian DNA repair and the DNA 
damage checkpoints. Annu Rev Biochem, 2004. 73: p. 39-85. 
30. Iyama, T. and D.M. Wilson, 3rd, DNA repair mechanisms in dividing and non-
dividing cells. DNA Repair (Amst), 2013. 12(8): p. 620-36. 
31. Bohgaki, T., M. Bohgaki, and R. Hakem, DNA double-strand break signaling and 
human disorders. Genome Integr, 2010. 1(1): p. 15. 
32. Haber, J.E., Recombination: a frank view of exchanges and vice versa. Curr Opin 
Cell Biol, 2000. 12(3): p. 286-92. 
33. Ferguson, D.O. and F.W. Alt, DNA double strand break repair and chromosomal 
translocation: lessons from animal models. Oncogene, 2001. 20(40): p. 5572-9. 
34. Takata, M., et al., Homologous recombination and non-homologous end-joining 
pathways of DNA double-strand break repair have overlapping roles in the 
maintenance of chromosomal integrity in vertebrate cells. EMBO J, 1998. 17(18): p. 
5497-508. 
35. Hung, P.J., et al., MRI Is a DNA Damage Response Adaptor during Classical Non-
homologous End Joining. Mol Cell, 2018. 71(2): p. 332-342 e8. 
36. Rathmell, W.K. and G. Chu, A DNA end-binding factor involved in double-strand 
break repair and V(D)J recombination. Mol Cell Biol, 1994. 14(7): p. 4741-8. 
37. Shibata, A., et al., Factors determining DNA double-strand break repair pathway 
choice in G2 phase. EMBO J, 2011. 30(6): p. 1079-92. 
38. Dobbs, T.A., J.A. Tainer, and S.P. Lees-Miller, A structural model for regulation of 
NHEJ by DNA-PKcs autophosphorylation. DNA Repair (Amst), 2010. 9(12): p. 
1307-14. 
39. Jiang, W., et al., Differential phosphorylation of DNA-PKcs regulates the interplay 
between end-processing and end-ligation during nonhomologous end-joining. Mol 
Cell, 2015. 58(1): p. 172-85. 
40. Ochi, T., et al., DNA repair. PAXX, a paralog of XRCC4 and XLF, interacts with Ku 
to promote DNA double-strand break repair. Science, 2015. 347(6218): p. 185-188. 
41. Cottarel, J., et al., A noncatalytic function of the ligation complex during 
nonhomologous end joining. Journal of Cell Biology, 2013. 200(2): p. 173-186. 
42. Graham, T.G.W., J.C. Walter, and J.J. Loparo, Two-Stage Synapsis of DNA Ends 
during Non-homologous End Joining. Molecular Cell, 2016. 61(6): p. 850-858. 
43. Buck, D., et al., Cernunnos, a novel nonhomologous end-joining factor, is mutated in 
human immunodeficiency with microcephaly. Cell, 2006. 124(2): p. 287-99. 
44. O'Driscoll, M., et al., DNA ligase IV mutations identified in patients exhibiting 
developmental delay and immunodeficiency. Mol Cell, 2001. 8(6): p. 1175-85. 
 67 
45. Woodbine, L., et al., PRKDC mutations in a SCID patient with profound 
neurological abnormalities. J Clin Invest, 2013. 123(7): p. 2969-80. 
46. Guo, C., et al., XRCC4 deficiency in human subjects causes a marked neurological 
phenotype but no overt immunodeficiency. J Allergy Clin Immunol, 2015. 136(4): p. 
1007-17. 
47. Bennardo, N., et al., Alternative-NHEJ is a mechanistically distinct pathway of 
mammalian chromosome break repair. PLoS Genet, 2008. 4(6): p. e1000110. 
48. Simsek, D. and M. Jasin, Alternative end-joining is suppressed by the canonical 
NHEJ component Xrcc4-ligase IV during chromosomal translocation formation. Nat 
Struct Mol Biol, 2010. 17(4): p. 410-6. 
49. Chang, H.H.Y., et al., Non-homologous DNA end joining and alternative pathways to 
double-strand break repair. Nat Rev Mol Cell Biol, 2017. 18(8): p. 495-506. 
50. Rulten, S.L. and G.J. Grundy, Non-homologous end joining: Common interaction 
sites and exchange of multiple factors in the DNA repair process. Bioessays, 2017. 
39(3). 
51. Callebaut, I., et al., Cernunnos interacts with the XRCC4 x DNA-ligase IV complex 
and is homologous to the yeast nonhomologous end-joining factor Nej1. J Biol 
Chem, 2006. 281(20): p. 13857-60. 
52. Vera, G., et al., Cernunnos deficiency reduces thymocyte life span and alters the T 
cell repertoire in mice and humans. Mol Cell Biol, 2013. 33(4): p. 701-11. 
53. Li, G., et al., Lymphocyte-specific compensation for XLF/cernunnos end-joining 
functions in V(D)J recombination. Mol Cell, 2008. 31(5): p. 631-40. 
54. Craxton, A., et al., XLS (c9orf142) is a new component of mammalian DNA double-
stranded break repair. Cell Death Differ, 2015. 22(6): p. 890-7. 
55. Xing, M., et al., Interactome analysis identifies a new paralogue of XRCC4 in non-
homologous end joining DNA repair pathway. Nat Commun, 2015. 6: p. 6233. 
56. Liu, X., et al., PAXX promotes KU accumulation at DNA breaks and is essential for 
end-joining in XLF-deficient mice. Nat Commun, 2017. 8: p. 13816. 
57. Balmus, G., et al., Synthetic lethality between PAXX and XLF in mammalian 
development. Genes Dev, 2016. 30(19): p. 2152-2157. 
58. Gago-Fuentes, R., et al., Normal development of mice lacking PAXX, the paralogue 
of XRCC4 and XLF. FEBS Open Bio, 2018. 8(3): p. 426-434. 
59. Abramowski, V., et al., PAXX and Xlf interplay revealed by impaired CNS 
development and immunodeficiency of double KO mice. Cell Death Differ, 2018. 
25(2): p. 444-452. 
60. Dutrannoy, V., et al., Clinical variability and novel mutations in the NHEJ1 gene in 
patients with a Nijmegen breakage syndrome-like phenotype. Hum Mutat, 2010. 
31(9): p. 1059-68. 
61. Recio, M.J., et al., Extreme Phenotypes With Identical Mutations: Two Patients With 
Same Non-sense NHEJ1 Homozygous Mutation. Front Immunol, 2018. 9: p. 2959. 
62. Kumar, V., F.W. Alt, and R.L. Frock, PAXX and XLF DNA repair factors are 
functionally redundant in joining DNA breaks in a G1-arrested progenitor B-cell 
line. Proc Natl Acad Sci U S A, 2016. 113(38): p. 10619-24. 
63. Dewan, A., et al., Robust DNA repair in PAXX-deficient mammalian cells. FEBS 
Open Bio, 2018. 8(3): p. 442-448. 
64. Lescale, C., et al., Specific Roles of XRCC4 Paralogs PAXX and XLF during V(D)J 
Recombination. Cell Rep, 2016. 16(11): p. 2967-2979. 
65. Castaneda-Zegarra, S., et al., Synthetic lethality between DNA repair factors Xlf and 
Paxx is rescued by inactivation of Trp53. DNA Repair (Amst), 2019. 73: p. 164-169. 
 68 
66. Efeyan, A. and M. Serrano, p53: guardian of the genome and policeman of the 
oncogenes. Cell Cycle, 2007. 6(9): p. 1006-10. 
67. Reinhardt, H.C. and B. Schumacher, The p53 network: cellular and systemic DNA 
damage responses in aging and cancer. Trends Genet, 2012. 28(3): p. 128-36. 
68. Gao, Y., et al., A targeted DNA-PKcs-null mutation reveals DNA-PK-independent 
functions for KU in V(D)J recombination. Immunity, 1998. 9(3): p. 367-76. 
69. Nussenzweig, A., et al., Requirement for Ku80 in growth and immunoglobulin V(D)J 
recombination. Nature, 1996. 382(6591): p. 551-5. 
70. Gu, Y., et al., Growth retardation and leaky SCID phenotype of Ku70-deficient mice. 
Immunity, 1997. 7(5): p. 653-65. 
71. Frank, K.M., et al., DNA ligase IV deficiency in mice leads to defective neurogenesis 
and embryonic lethality via the p53 pathway. Mol Cell, 2000. 5(6): p. 993-1002. 
72. Gao, Y., et al., A critical role for DNA end-joining proteins in both lymphogenesis 
and neurogenesis. Cell, 1998. 95(7): p. 891-902. 
73. Oksenych, V., et al., Functional redundancy between the XLF and DNA-PKcs DNA 
repair factors in V(D)J recombination and nonhomologous DNA end joining. Proc 
Natl Acad Sci U S A, 2013. 110(6): p. 2234-9. 
74. Rooney, S., et al., Artemis-independent functions of DNA-dependent protein kinase 
in Ig heavy chain class switch recombination and development. Proc Natl Acad Sci U 
S A, 2005. 102(7): p. 2471-5. 
75. Gao, Y., et al., Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, 
genomic stability and development. Nature, 2000. 404(6780): p. 897-900. 
76. Xing, M., et al., Synthetic lethality between murine DNA repair factors XLF and 
DNA-PKcs is rescued by inactivation of Ku70. DNA Repair (Amst), 2017. 57: p. 
133-138. 
77. Jacks, T., et al., Tumor spectrum analysis in p53-mutant mice. Curr Biol, 1994. 4(1): 
p. 1-7. 
78. Franco, S., et al., H2AX prevents DNA breaks from progressing to chromosome 
breaks and translocations. Mol Cell, 2006. 21(2): p. 201-14. 
79. Oksenych, V., et al., Functional redundancy between repair factor XLF and damage 
response mediator 53BP1 in V(D)J recombination and DNA repair. Proc Natl Acad 
Sci U S A, 2012. 109(7): p. 2455-60. 
80. Frank, K.M., et al., Late embryonic lethality and impaired V(D)J recombination in 
mice lacking DNA ligase IV. Nature, 1998. 396(6707): p. 173-7. 
81. Hung, P.J., et al., Deficiency of XLF and PAXX prevents DNA double-strand break 
repair by non-homologous end joining in lymphocytes. Cell Cycle, 2017. 16(3): p. 
286-295. 
82. Ouyang, H., et al., Ku70 is required for DNA repair but not for T cell antigen 
receptor gene recombination In vivo. J Exp Med, 1997. 186(6): p. 921-9. 
83. Guevara, N.V., et al., The absence of p53 accelerates atherosclerosis by increasing 
cell proliferation in vivo. Nat Med, 1999. 5(3): p. 335-9. 
84. Jones, S.N., et al., The tumorigenic potential and cell growth characteristics of p53-
deficient cells are equivalent in the presence or absence of Mdm2. Proc Natl Acad 
Sci U S A, 1996. 93(24): p. 14106-11. 
85. Moureau, S., et al., A role for the p53 tumour suppressor in regulating the balance 




Appendix A: Primer sequences and expected WT and mutant amplicons of Paxx, Xlf, Trp53, 
Ku80 and Dna-pkcs. 
 
 






WT 965bp  







































WT 250bp  
Mutant 427bp 
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Appendix B: PCR Programs 
A 
Paxx (WT/Mutant) 
Step Time Temperature (°C) Cycles 
Initial denaturation 2 min 94 1 
Denaturation 30 sec 94 
30 Annealing 45 sec 68 
Elongation 1 min 72 
Final extension 5 min 72 1 





Step Time Temperature (°C) Cycles 
Initial denaturation 3 min 95 1 
Denaturation 30 sec 95 
40 Annealing & 
elongation 
1 min 62 
Final extension 5 min 68 1 










Step Time Temperature (°C) Cycles 
Initial denaturation 2 min 95 1 
Denaturation 30 sec 95 
30 Annealing 30 sec 67 
Elongation 20 sec 72 
Final extension 5 min 72 1 




Step Time Temperature (°C) Cycles 
Initial denaturation 2 min 94 1 
Denaturation 20 sec 94 
40 Annealing 15 sec 61 
Elongation 40 sec 72 
Final extension 5 min 72 1 










Step Time Temperature (°C) Cycles 
Initial denaturation 3 min 94 1 
Denaturation 45 sec 94 
30 Annealing 45 sec 66 
Elongation 1 min 72 
Final extension 5 min 72 1 




Step Time Temperature (°C) Cycles 
Initial denaturation 3 min 94 1 
Denaturation 45 sec 94 
40 Annealing 45 sec 59,5 
Elongation 1 min 72 
Final extension 5 min 72 1 
Hold ∞ 4  
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